124 related articles for article (PubMed ID: 12646307)
1. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
[TBL] [Abstract][Full Text] [Related]
2. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
Cook SA; Lowe JA; Martin BR
J Pharmacol Exp Ther; 1998 Jun; 285(3):1150-6. PubMed ID: 9618417
[TBL] [Abstract][Full Text] [Related]
3. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
4. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
Beardsley PM; Martin BR
Eur J Pharmacol; 2000 Jan; 387(1):47-53. PubMed ID: 10633159
[TBL] [Abstract][Full Text] [Related]
5. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.
Yamaguchi T; Hagiwara Y; Tanaka H; Sugiura T; Waku K; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2001 Aug; 909(1-2):121-6. PubMed ID: 11478928
[TBL] [Abstract][Full Text] [Related]
6. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
Tanda G; Loddo P; Di Chiara G
Eur J Pharmacol; 1999 Jul; 376(1-2):23-6. PubMed ID: 10440085
[TBL] [Abstract][Full Text] [Related]
7. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
Lichtman AH; Fisher J; Martin BR
Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
[TBL] [Abstract][Full Text] [Related]
8. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
Tsou K; Patrick SL; Walker JM
Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome.
Rubino T; Massi P; Viganò D; Fuzio D; Parolaro D
Life Sci; 2000 Apr; 66(22):2213-9. PubMed ID: 10834304
[TBL] [Abstract][Full Text] [Related]
11. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Dhawan K; Kumar S; Sharma A
J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
[TBL] [Abstract][Full Text] [Related]
12. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.
Aceto MD; Scates SM; Lowe JA; Martin BR
J Pharmacol Exp Ther; 1996 Sep; 278(3):1290-5. PubMed ID: 8819514
[TBL] [Abstract][Full Text] [Related]
13. Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: a quasi abstinence approach.
Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2005 Dec; 1066(1-2):201-5. PubMed ID: 16336946
[TBL] [Abstract][Full Text] [Related]
14. Precipitated and spontaneous withdrawal in rats tolerant to anandamide.
Costa B; Giagnoni G; Colleoni M
Psychopharmacology (Berl); 2000 Apr; 149(2):121-8. PubMed ID: 10805606
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.
Aceto MD; Scates SM; Lowe JA; Martin BR
Eur J Pharmacol; 1995 Aug; 282(1-3):R1-2. PubMed ID: 7498260
[TBL] [Abstract][Full Text] [Related]
17. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action.
Ko MC; Woods JH
Psychopharmacology (Berl); 1999 Apr; 143(3):322-6. PubMed ID: 10353438
[TBL] [Abstract][Full Text] [Related]
18. Differential disruption of response alternation by precipitated Δ
Eckard ML; Kinsey SG
Pharmacol Biochem Behav; 2024 Mar; 236():173718. PubMed ID: 38272272
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid receptors and reward in the rat: a conditioned place preference study.
Cheer JF; Kendall DA; Marsden CA
Psychopharmacology (Berl); 2000 Jul; 151(1):25-30. PubMed ID: 10958113
[TBL] [Abstract][Full Text] [Related]
20. Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats.
Yamaguchi T; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2001 Jan; 889(1-2):149-54. PubMed ID: 11166698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
